This whitepaper, developed from a survey by Median Technologies and Citeline, delves into the complexities of managing reader variability in radiological imaging for oncology clinical trials. With oncology remaining a major focus for pharmaceutical R&D, ensuring accurate image interpretation is critical for evaluating novel therapies.
The whitepaper highlights the role of Blinded Independent Central Review (BICR) in managing variability and explores strategies for improving image reading accuracy. It also looks ahead to how advanced technologies like AI and machine learning can transform the future of imaging in clinical trials.